Cleerly Demonstrates Significant Cardiovascular Risk Prediction in Late-Breaking Clinical Science at European Society of Cardiology Congress 2025

Audio By Carbonatix

DENVER--(BUSINESS WIRE)--Sep 3, 2025--

Cleerly, a leader in AI-based cardiovascular imaging, presented a late-breaking analysis of registry data, Prognostic Value of AI-based Quantitative Coronary CT Evaluation Versus Standard Qualitative Evaluation, and five additional research abstracts at the European Society of Cardiology (ESC) Congress 2025, August 29 - September 1 at the Institución Ferial de Madrid (IFEMA) in Madrid, Spain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903888828/en/

Cleerly demonstrates significant cardiovascular risk prediction in late-breaking clinical science at European Society of Cardiology Congress 2025. This AI-powered coronary assessment provides incremental prognostic value over traditional visual assessment methods for predicting major adverse cardiovascular events.

Cleerly presented late-breaking results from the CONFIRM2 registry, which demonstrated that the addition of AI-based quantitative Coronary CT Angiography (AI-QCT) significantly improved risk discrimination compared to models combining other clinical predictors such as CAD-RADS 2.0, coronary artery calcium score (CAC), and DUKE CAD index used for predicting Major Adverse Cardiovascular Events (MACE).

CONFIRM2 1 is a multicenter, international, observational cohort targeting 30,000 patients, with more than 8,000 participants currently enrolled, that aims to perform comprehensive quantification of CT angiography findings and relate them to clinical variables and cardiovascular clinical outcomes. For this ESC late-breaker, investigators analyzed a symptomatic subset of the cohort with available manual CAD-RADS and CAC scores. AI-QCT was applied to quantify plaque burden, morphology, composition, and luminal obstruction across the coronary tree, and predictive modeling was performed using quantitative diameter stenosis and non-calcified plaque volume.

"This research shows we can now identify patients at risk for MACE with greater precision than ever before," said Ibrahim Danad, MD, PhD, of Radboud University Medical Center and principal investigator.

Principal investigator Alexander van Rosendael, MD, PhD, from Leiden University Medical Center, who presented the results at ESC, stated, "Plaque burden quantification by AI-QCT provides critical insights that standard CT evaluation will miss, especially in patients with mild to moderate disease who represent a significant portion of our patient population."

Key findings include:

• AI-QCT provided incremental prognostic information over CAD-RADS, coronary artery calcium scoring, and the Duke Index
• The addition of AI-QCT significantly improved risk stratification compared to the CAD-RADS (AUC 0.81 vs 0.79, p<0.001), the CAC score (AUC 0.79 vs 0.70, p<0.001), and the DUKE Index (0.81 vs 0.76, p<0.001)
• The greatest benefit of the addition of AI-QCT was observed in patients without severe stenosis

Additional Research Abstracts

Cleerly also presented five additional abstracts covering advances in stenosis quantification, diagnostic performance across patient populations, and sex-based differences in plaque assessment:

• Optimizing Stenosis Quantification by a Novel Interpolation-Based Approach: Diagnostic Performance Data from CREDENCE and PACIFIC-1
• Diagnostic Performance of a Novel AI Algorithm for Determining Coronary Ischemia (AI-QCT ISCHEMIA) According to Patient Comorbidities
• Pooled-Analysis Comparing Accuracy of Cleerly ISCHEMIA vs. FFRCT
• Sex Based Differences in Association with Plaque Burden and Ischemia — a CREDENCE Trial Substudy
• Differential Atherosclerotic Burden and Ischemic Risk Across Major Coronary Arteries: a Comparative Analysis Using Quantitative Coronary Computed Tomography Angiography; a CREDENCE Trial Substudy

For more information about Cleerly's groundbreaking cardiovascular research and technology, visit www.cleerlyhealth.com.

About Cleerly

Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.

References:

1. Van Rosendael AR, Crabtree T, Bax JJ, Nakanishi R, Mushtaq S, Pontone G, Andreini D, Buechel RR, Gräni C, Feuchtner G, Patel TR, Choi AD, Al-Mallah M, Nabi F, Karlsberg RP, Rochitte CE, Alasnag M, Hamdan A, Cademartiri F, Marques H, Kalra D, German DM, Gupta H, Hadamitzky M, Deaño RC, Khalique O, Knaapen P, Hoffmann U, Earls J, Min JK, Danad I; CONFIRM 2 investigators. Rationale and design of the CONFIRM2 (Quantitative COroNary CT Angiography Evaluation For Evaluation of Clinical Outcomes: An InteRnational, Multicenter Registry) study. J Cardiovasc Comput Tomogr. 2024 Jan-Feb;18(1):11-17. doi: 10.1016/j.jcct.2023.10.004. Epub 2023 Nov 10. PMID: 37951725; PMCID: PMC10923095.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250903888828/en/

CONTACT: Cleerly Media Contact

Christy Sievert

press@cleerlyhealth.com

KEYWORD: COLORADO EUROPE SPAIN UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SOFTWARE RESEARCH INTERNET APPS/APPLICATIONS MEDICAL DEVICES TECHNOLOGY ARTIFICIAL INTELLIGENCE HEALTH TECHNOLOGY SCIENCE CARDIOLOGY AUDIO/VIDEO HEALTH

SOURCE: Cleerly

Copyright Business Wire 2025.

PUB: 09/03/2025 10:00 AM/DISC: 09/03/2025 09:59 AM

http://www.businesswire.com/news/home/20250903888828/en